Oncotarget

Meta-Analysis:

Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis

Ling Peng, Yina Wang, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang and Qiong Zhao _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:83280-83291. https://doi.org/10.18632/oncotarget.21059

Metrics: PDF 1717 views  |   HTML 1806 views  |   ?  


Abstract

Ling Peng1,*, Yina Wang1,*, Yun Hong2, Xianghua Ye3, Peng Shi4,5, Junyan Zhang6 and Qiong Zhao1

1Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

2Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

3Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

4Department of Medical Statistics, Children’s Hospital of Fudan University, Shanghai, China

5Center for Evidence-based Medicine, Fudan University, Shanghai, China

6Bothwin Clinical Study Consultant, Bellevue, WA, USA

*These authors contributed equally to this work

Correspondence to:

Qiong Zhao, email: [email protected]

Keywords: BRAF inhibitor, MEK inhibitor, cuSCC, meta-analysis

Received: July 25, 2017     Accepted: August 28, 2017     Published: September 19, 2017

ABSTRACT

Background: BRAF inhibitor and dual BRAF/MEK inhibitors have been approved for the treatment of BRAF-mutated melanoma. Cutaneous squamous cell carcinoma (cuSCC) is an adverse event associated with these drugs. The contribution of BRAF inhibitor and dual BRAF/MEK inhibitors to cuSCC are still unknown. We performed this meta-analysis to determine the overall incidence and relative risk of cuSCC in cancer patients treated with these drugs.

Results: A total of 7,442 patients from 24 primary studies were included. The incidences of all-grade and high-grade cuSCC in cancer patients treated with BRAF inhibitor were 12.5% (95% CI: 10.8–14.6%) and 11.6% (95% CI: 9.8–13.8%), and dual BRAF/MEK inhibitors were 3.0% (95% CI: 2.0–4.5%) and 2.8% (95% CI: 1.9–4.0%), respectively. On subgroup analysis and meta-regression, the incidence of cuSCC did not vary with tumor type, study design and specific drug used. The use of single agent BRAF inhibitor significantly increased the risk of developing cuSCC comparing with dual BRAF/MEK inhibitors for all-grade (RR 4.72, 95% CI: 2.42–9.20) and high-grade (RR 4.92, 95% CI: 2.64–9.16) in cancer patients.

Materials and Methods: The databases of PubMed, Embase and abstracts published in ASCO proceedings were searched for relevant studies from January 2000 to June 2017. Summary incidences, relative risks (RRs) and 95% confidence intervals (CIs) were calculated by using either random effects or fixed effect models according to the heterogeneity of included studies.

Conclusions: BRAF inhibitor significantly increases the risk of developing cuSCC compared with dual BRAF/MEK inhibitors in cancer patients. Clinicians should be aware of the risks of cuSCC with the administration of these drugs in cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21059